Jerusalem Pharmaceutical Co (XPAE:JPH) Institutional Ownership: 0.56% (As of Sep. 15, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XPAE:JPH Jerusalem Pharmaceutical Co XPAE:JPH
75 GF Score
Price $3.55
GF Value $2.47
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Jerusalem Pharmaceutical Co Institutional Ownership?

Jerusalem Pharmaceutical Co XPAE:JPH -2.47% 75 Institutional Ownership is 0.56% as of Sep. 15, 2026. GuruFocus rates XPAE:JPH with a GF Score™ of 75/100 and a GF Value™ of $2.47 (Significantly Overvalued). The stock has 6 warning signs investors should review.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Jerusalem Pharmaceutical Co's institutional ownership is 0.56%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Jerusalem Pharmaceutical Co's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Jerusalem Pharmaceutical Co's Float Percentage Of Total Shares Outstanding is 0.00%.

Jerusalem Pharmaceutical Co Institutional Ownership Historical Data

* Premium members only.

The historical data trend for Jerusalem Pharmaceutical Co's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Jerusalem Pharmaceutical Co Institutional Ownership Chart

Jerusalem Pharmaceutical Co Historical Data

The historical data trend for Jerusalem Pharmaceutical Co can be seen below:

2023-05-31 2023-06-30 2023-07-31 2023-08-31 2023-09-30 2023-11-30 2023-12-31 2024-01-31 2024-02-29 2024-03-31
Institutional Ownership 0.56 0.56 0.56 0.56 0.56 0.56 0.56 0.56 0.56 0.56
XPAE:JPH
75GF Score
Jerusalem Pharmaceutical Co XPAE:JPH
Institutional Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Jerusalem Pharmaceutical Co Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 0.56% mean?
Jerusalem Pharmaceutical Co (XPAE:JPH) has a Institutional Ownership of 0.56% as of Sep. 15, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Jerusalem Pharmaceutical Co and its competitors.
Is Jerusalem Pharmaceutical Co's Institutional Ownership too high?
Jerusalem Pharmaceutical Co's current Institutional Ownership is 0.56%. Overall, Jerusalem Pharmaceutical Co has a GF Score™ of 75/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Jerusalem Pharmaceutical Co's Institutional Ownership compare to ZTS and UTHR?
Jerusalem Pharmaceutical Co's Institutional Ownership of 0.56% can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Drug Manufacturers company?
A good Institutional Ownership depends on the Drug Manufacturers industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Jerusalem Pharmaceutical Co and its competitors. Jerusalem Pharmaceutical Co's current Institutional Ownership is 0.56%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jerusalem Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Jerusalem Pharmaceutical Co (XPAE:JPH) is currently considered Significantly Overvalued. The stock's GF Value™ is $2.47, compared to a current price of $3.55 — trading 43.7% above its estimated fair value. The current Institutional Ownership is 0.56%. Jerusalem Pharmaceutical Co's overall GF Score™ is 75/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For Jerusalem Pharmaceutical Co (XPAE:JPH), the current Institutional Ownership is 0.56% as of Sep. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Jerusalem Pharmaceutical Co (XPAE:JPH) Overvalued in 2026?

Based on GuruFocus' analysis, Jerusalem Pharmaceutical Co stock appears to be overvalued. The current stock price of $3.55 is trading 43.7% above its estimated GF Value™ of $2.47. GuruFocus considers Jerusalem Pharmaceutical Co to be Significantly Overvalued.

Key valuation signals for XPAE:JPH:

  • Institutional Ownership: 0.56%
  • GF Value™: $2.47 vs. price of $3.55 (43.7% above fair value)
  • GF Score™: 75/100 with 6 warning signs

No single metric tells the full story. See the XPAE:JPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Jerusalem Pharmaceutical Co Business Description

Address Nablus Street, Jerusalem Pharmaceuticals Company Buliding, Al Bireh Industrial Zone, Al Bireh, PSE, 3570
Jerusalem Pharmaceutical Co is engaged in developing, manufacturing and marketing of human pharmaceuticals products. It also produces detergent, cosmetic, personal and home care products, veterinary and agricultural products. The company operates in Jordan, Algeria, the Middle East, and North Africa Region. Its product portfolio contains more than 300 pharmaceutical products in various dosage forms including tablets, capsules, sterile injectables, powders for suspensions, suspensions, syrups, powders, suppositories, ovules, creams, ointments, as well as ear and nose drops and solutions.
75GF Score

Get the complete analysis for XPAE:JPH

Institutional Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.55
Price
$2.47
GF Value